Ryan Deschner

Stock Analyst at Raymond James

(4.81)
# 113
Out of 5,182 analysts
20
Total ratings
88.89%
Success rate
72.98%
Average return

Stocks Rated by Ryan Deschner

Apellis Pharmaceuticals
Apr 1, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $40.95
Upside: -
Palvella Therapeutics
Nov 19, 2025
Upgrades: Strong Buy
Price Target: $92$143
Current: $128.64
Upside: +11.16%
Tvardi Therapeutics
Oct 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $3.05
Upside: -
Liquidia
Aug 13, 2025
Maintains: Strong Buy
Price Target: $33$41
Current: $37.34
Upside: +9.80%
Trevi Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29$27
Current: $14.27
Upside: +89.21%
Ardelyx
Aug 5, 2025
Maintains: Outperform
Price Target: $11$12
Current: $5.99
Upside: +100.33%
Viking Therapeutics
Jul 24, 2025
Maintains: Strong Buy
Price Target: $125$122
Current: $32.99
Upside: +269.87%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26$28
Current: $7.95
Upside: +252.20%